Tegoprazan is under clinical development by Sebela Pharmaceuticals and currently in Phase III for Reflux Esophagitis (Gastroesophageal Reflux Disease). According to GlobalData, Phase III drugs for Reflux Esophagitis (Gastroesophageal Reflux Disease) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tegoprazan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tegoprazan overview

Tegoprazan (RQ-00000004, CJ-12420) is a benzimidazole derivative acts as antiulcer agent. It is formulated as film coated tablets for oral route of administration. Tegoprazan is indicated for the treatment of of erosive esophagitis (EE) and non-erosive reflux disease (NERD).

(RQ-00000004, CJ-12420) is under development for the treatment of functional dyspepsia, gastro esophageal reflux diseases (GERD), non-erosive reflux disease, gastric ulcers, helicobacter pylori infections and duodenal ulcers. The drug candidate is an oral, selective and reversible gastric acid pump antagonist. The drug candidate is a potassium-competitive acid blocker (P-CAB) that inhibits the binding of potassium ion to H+/K+-ATPase.

Sebela Pharmaceuticals overview

Sebela Pharmaceuticals is a US-based developer of prescription pharmaceutical products. It offers products such as Suprep, Sutab, Golytely, Analpharm Hc, Lotronex, Motofen, Naftifine, Pramosone, Imuran, Ridaura, Pexeva and Brisdelle, in the areas of gastroenterology, women’s health, dermatology, podiatrist and others. It offers products in the US and outside the Us through distributors and marketing partners. Sebela Pharmaceuticals is headquartered in Georgia, the US.

For a complete picture of Tegoprazan’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.